Lesson plan

STC3141

STC3141 is an extracellular histone neutralizer which is under development for the treatment of sepsis and COVID-19 pneumonia. It is given by intravenous infusion. The drug is a carbohydrate-based polyanion molecule of β-O-methyl cellobiose sulfate sodium salt (mCBS.Na). It may limit inflammation and organ damage in sepsis by blocking toxic circulating histones in the condition. Accordingly, the drug showed preliminary efficacy in reducing sepsis in a phase 2 clinical trial. STC3141 was developed by Griffith University and the Australian National University and is under development by Grand Pharmaceutical Group in China. As of January 2026, it is in phase 2 trials, with a phase 3 trial being planned.

Back to article

Article summary

STC3141 is an extracellular histone neutralizer which is under development for the treatment of sepsis and COVID-19 pneumonia. It is given by intravenous infusion. The drug is a carbohydrate-based polyanion molecule of β-O-methyl cellobiose sulfate sodium salt (mCBS.Na). It may limit inflammation and organ damage in sepsis by blocking toxic circulating histones in the condition. Accordingly, the drug showed preliminary efficacy in reducing sepsis in a phase 2 clinical trial. STC3141 was developed by Griffith University and the Australian National University and is under development by Grand Pharmaceutical Group in China. As of January 2026, it is in phase 2 trials, with a phase 3 trial being planned.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.